Rezolute’s (RZLT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Rezolute (NASDAQ:RZLT) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $14.00 price objective on the stock. HC Wainwright also issued estimates for Rezolute’s Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.23) EPS, Q1 2025 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($1.72) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at $2.28 EPS.

RZLT has been the subject of a number of other research reports. JMP Securities reiterated a market outperform rating and set a $7.00 price objective on shares of Rezolute in a research note on Thursday, April 18th. Jonestrading began coverage on Rezolute in a research note on Thursday, April 18th. They set a buy rating and a $10.00 price objective for the company. Finally, Maxim Group began coverage on Rezolute in a research note on Tuesday, April 9th. They issued a buy rating and a $8.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of Buy and an average price target of $8.80.

Rezolute Stock Performance

NASDAQ RZLT opened at $3.56 on Wednesday. The stock has a 50-day simple moving average of $2.68 and a two-hundred day simple moving average of $1.67. The firm has a market capitalization of $142.86 million, a P/E ratio of -3.12 and a beta of 1.29. Rezolute has a fifty-two week low of $0.72 and a fifty-two week high of $3.72.

Insider Activity at Rezolute

In other Rezolute news, Director Young-Jin Kim purchased 36,503 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was purchased at an average price of $1.91 per share, for a total transaction of $69,720.73. Following the purchase, the director now directly owns 115,450 shares in the company, valued at $220,509.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Young-Jin Kim acquired 36,503 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were bought at an average cost of $1.91 per share, for a total transaction of $69,720.73. Following the acquisition, the director now owns 115,450 shares in the company, valued at approximately $220,509.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daron Evans acquired 20,000 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was purchased at an average price of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the acquisition, the chief financial officer now owns 20,000 shares in the company, valued at approximately $33,800. The disclosure for this purchase can be found here. Insiders acquired a total of 124,503 shares of company stock worth $232,821 in the last 90 days. Corporate insiders own 20.80% of the company’s stock.

Institutional Investors Weigh In On Rezolute

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Rezolute in the 1st quarter worth about $37,000. Acadian Asset Management LLC acquired a new stake in Rezolute in the 1st quarter worth about $229,000. Vanguard Group Inc. boosted its holdings in Rezolute by 10.4% in the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock worth $3,961,000 after buying an additional 145,700 shares during the last quarter. Rosalind Advisors Inc. acquired a new stake in Rezolute in the 1st quarter worth about $510,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Rezolute in the 1st quarter worth about $4,080,000. 82.97% of the stock is currently owned by institutional investors and hedge funds.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.